Tag Archives: migraine

Enhancing Brain Detoxification: A New Approach to Migraine Relief

Posted on by
Reply
Novel Migraine Research

Innovative Strategies for Migraine Relief

Sergey Khakimullin/Getty Images

About one-third of migraine sufferers find no relief from standard treatments. However, new research suggests that utilizing the brain’s waste-clearing system could introduce innovative treatment methods. A particular drug that is typically used to manage high blood pressure demonstrated the ability to effectively eliminate chemicals from the brains of mice that contribute significantly to migraines. Consequently, the mice showed minimal facial pain.

Around 60% of migraine patients experience considerable discomfort during episodes.

Globally, approximately 1 in 7 people suffer from migraines. Symptoms include pain, pressure, and tingling in areas such as the cheeks, jaw, forehead, and behind the eyes, often worsened even by light touch. “Just brushing your hair can result in excruciating pain for those living with migraines,” stated Adriana Della Pietra, who presented findings at the Oxford Glymphatic and Brain Clearance Symposium in the UK on April 1.

Conventional treatments for migraines, including triptans, aim to reduce inflammation and lower the levels of a neurotransmitter known as calcitonin gene-related peptide (CGRP), a key player in migraine pathology. CGRP is a major factor driving migraines, targeted by many standard treatments. “Unfortunately, many individuals do not respond to these medications and are frequently trapped in a cycle of debilitating pain,” commented Valentina Mosienko from the University of Bristol, UK, who was not involved in the study.

In previous studies, researchers discovered that prazosin, a medication prescribed for high blood pressure, alleviated facial pain caused by traumatic brain injuries in mice. Traumatic injuries can impair the brain’s waste disposal system, known as the glymphatic system, and prazosin enhanced fluid flow from brain cells through this system. Interestingly, it also appeared to benefit some migraine models used as control groups.

To delve deeper, the research team administered prazosin to one group of mice in their drinking water over six weeks, comparing against a control group that received standard water. Subsequently, both groups were subjected to migraines induced by CGRP injections.

After 30 minutes, the researchers applied progressively thicker plastic filaments to the mice’s foreheads. This technique, normally non-painful, became more detectable as the filaments increased in thickness. The findings showed that mice receiving prazosin managed to endure significantly thicker filaments without flinching compared to control mice. Della Pietra noted that the prazosin group behaved similarly to mice that hadn’t received CGRP injections.

Further analysis revealed that prazosin not only reversed the impairment of the glymphatic system caused by CGRP but also likely enhanced the clearance of CGRP and other pain-transmitting molecules, as reported by Della Pietra.

Research teams are eager to examine whether similar results can be replicated in humans. “If it proves effective in humans, that would be a tremendous breakthrough,” Mosienko added. “Since this drug is already in use, we have established safety for its application.”

Topics:

Source: www.newscientist.com

Breakthrough Insights into Migraine Causes Uncover New Drug Targets

Posted on by
Reply
Trigeminal Nerve and Migraine Treatment

The trigeminal nerve is a critical target in migraine treatment.

Jitendra Jadhav/Alamy

There is a new wave of migraine treatments on the horizon, focusing on a previously overlooked neural pathway that may provide relief. Understanding various migraine mechanisms is essential, given that migraines affect over 1 billion people globally, especially those who do not respond to standard therapies.

Despite past failures in drug trials, skepticism about this neural pathway’s significance is fading. Recent placebo-controlled studies call for a reevaluation of earlier assumptions about its role in migraine treatment.

Mehsud Ashina and his team at the University of Copenhagen investigated substance P, a neuropeptide linked to migraines. This crucial molecule, released by the trigeminal nerve, leads to pain through blood vessel dilation and inflammation in the meninges, thus amplifying pain signals.

Recent findings show that substance P injections induce headaches, with 71% of non-migraine individuals exhibiting dilation of the superficial temporal artery, a response similar to that seen in migraine sufferers, validating substance P’s role in these conditions.

Following the late 1990s dismissal of substance P as a viable target for migraine drugs, largely due to previous drug failures, Ashina’s team proposed that simplicistic targeting of a single receptor, the neurokinin-1 receptor (NK1-R), was misguided. It is known now that substance P interacts with multiple receptors, including MRGPRX2, enhancing pain signals.

“Previous trials failed because they targeted NK1-R alone,” Ashina explains. Michael Moskowitz at Harvard recognized the trigeminal nerve’s pivotal role in migraines. “Blocking substance P’s broad effects could open new therapeutic doors. With our evolving knowledge, it’s time to revisit this strategy.”

Current advancements allow for monoclonal antibodies that block substance P directly. These innovations have already proven effective against another migraine target, calcitonin gene-related peptide (CGRP), while also exploring pituitary adenylate cyclase-activating polypeptide (PACAP).

Recently, Danish pharmaceutical company Lundbeck presented initial findings from a randomized controlled trial on an anti-PACAP monoclonal antibody called Bocnevert, which reportedly decreased monthly migraine days compared to a placebo. “This data is a positive development,” says Lars Edvinson from Lund University. Full results are expected to be shared at an upcoming conference.

With this shift in focus, there’s potential to reduce reliance on CGRP inhibitors, which have transformed migraine management since their U.S. approval in 2018, effectively halving migraine days for many. However, 40% of users still struggle.

“While CGRP drugs are effective for many, they are not universal,” says Peter Goadsby from King’s College Hospital, who collaborated on CGRP research in the 1990s. “Finding new solutions for the millions still underserved remains a pressing challenge.”

Further research is expected on the impact of inhibiting these peptides. “Substance P, CGRP, and PACAP interact with the meningeal vessel wall but do so uniquely, so there is room for optimism,” Moskowitz adds. A combination approach targeting multiple pathways may enhance treatment efficacy for non-responders.

However, it is uncertain whether drugs targeting substance P and PACAP will eclipse the effects of CGRP antagonists, which are released in higher quantities from the trigeminal nerve. “I do not believe that these alternatives can fully replace CGRP’s impact,” Edvinsson states.

Topics:

Source: www.newscientist.com

Migraine Medications That Alleviate Headaches and Dizziness Symptoms

Posted on by
Reply

The debilitating nature of migraines can significantly hinder a person’s daily routine

Alfred Pasieka/Science Photo Library

A medication called Ubrogepant, which is currently prescribed for migraine treatment, has been found to alleviate non-headache symptoms that often precede the onset of migraines. This makes it the first medication known to address these initial signs.

Before migraine headaches decrease in intensity, many individuals experience warning signs such as light sensitivity, sounds, dizziness, and neck stiffness, all of which can significantly disrupt daily activities.

Developers of migraine medications have predominantly concentrated on treating the headaches themselves, with no effective solutions available for alleviating these preliminary symptoms.

However, Ubrogepant demonstrated promising results when administered during the early stages of migraine symptoms, according to Peter Goadsby from King’s College London and his team, who are eager to further explore this potential.

Their study involved 438 participants, aged 18 to 75, all with a history of migraines. Half received a 100 mg dose of the medication upon experiencing suggestive symptoms of an impending migraine. The other half took a placebo during a subsequent episode of prodromal symptoms.

Following the administration of Ubrogepant, participants reported an enhanced ability to focus after 1 hour, decreased sensitivity to light after 2 hours, and reduced fatigue and neck discomfort after 3 hours, compared to their experiences while taking the placebo. They also noted less sensitivity to dizziness and sound when using Ubrogepant.

“Taking Ubrogepant allowed individuals to mitigate these non-pain symptoms even before the headache began,” Goadsby remarked.

This study did not delve into the impact of the medication on aura, another early feature of migraines that includes sensory disturbances like flashing lights or blind spots.

“The potential for intervention in the migraine progression is clinically significant given the often debilitating early symptoms,” remarked Parisa Gazerani from Oslo Metropolitan University, Norway. However, she emphasizes the need for further studies to ensure broad applicability.

“This research indicates that migraine treatments could lessen these preliminary symptoms and may prevent the progression to the main headache phase,” stated Rob Music, head of the Migraine Trust in the UK. “We are eager to see more investigations in this area to lessen the burden of migraines on daily living.”

topic:

Source: www.newscientist.com

Migraine Medications Are Ineffective in Alleviating Dizziness Symptoms

Posted on by
Reply

Here’s a rewritten version of your content while keeping the HTML tags intact:

Rizatriptan is frequently recommended for various migraine types

Aleksandr Zubkov/Getty Images

The standard medications prescribed for migraines provide limited relief for the vestibular symptoms, which include dizziness and typical migraine manifestations like headaches and light sensitivity. This is true even for rizatriptan, which is sometimes recommended for such types of migraines.

Research on vestibular migraine treatment has been inconsistent, yielding mixed results across different medications, according to Jeffrey Staab from the Mayo Clinic in Rochester, Minnesota. Some newer medications, like galcanezumab, may reduce the frequency of attacks, but no randomized trials have previously evaluated the effectiveness of migraine medications in alleviating vestibular symptoms during episodes.

To fill this research gap, Staab and his team investigated vestibular migraines. Participants were instructed to take 10 milligrams of rizatriptan or a placebo at the onset of vestibular symptoms, such as balance problems and spinning sensations. Their symptoms were subsequently evaluated on a scale of 0 to 3 at several intervals until the episodes resolved.

One hour after administration—at which point rizatriptan reaches peak concentrations in the bloodstream—it was not more effective than the placebo in relieving symptoms which are often considered to act quickly. Both groups were allowed to use back-up medications after waiting the necessary hour.

After 24 hours, rizatriptan showed a slight improvement in sensitivity to movement, light, and sound, but not in dizziness. Participants also reported marginally higher scores concerning physical well-being—such as energy levels and the ability to carry out daily activities—when compared to those taking the placebo. However, no differences were noted in mental well-being or the acceptance of side effects.

Rizatriptan falls under the triptans class of drugs, typically effective against migraines, but may not alleviate vestibular symptoms, as noted by Staab.

The study’s findings indicate that the brain pathways linked to vestibular migraines (the vestibular system, which is considered “primitive” from an evolutionary standpoint) may lack sensitivity to triptans for reasons that are yet to be explored. According to Peter Goadsby from King’s College London, vestibular migraines should not be treated as distinct conditions from other migraine types; rather, their symptoms represent a “slight variation” of migraine pathology that necessitates targeted treatment approaches.

“I think it’s important to communicate with fellow clinicians about these symptoms,” Goadsby states. “For instance, if you are treating someone with a vestibular migraine using a triptan, be prepared for it to potentially be ineffective. It’s crucial to recognize that this doesn’t imply the patient is difficult or unreasonable.”

Topics:

This retains the original HTML structure while rephrasing the content for clarity and flow.

Source: www.newscientist.com

New Drug Nearing Breakthrough for Migraine Treatment

Posted on by
Reply

Those who suffer from the throbbing pain of migraines know how challenging everyday tasks can become. However, a new medication, if taken at the first signs of a migraine, could potentially prevent the onset of debilitating symptoms.

The drug, ubrogepant, has recently been approved for use in the US and is available in the UK, although not covered by the NHS. A study funded by AbbVie, the manufacturer of ubrogepant, revealed that taking the pill at the first indication of a migraine can prevent severe headaches from developing.

Before a migraine attack, some individuals experience early warning signs like sensitivity to light and sound, fatigue, neck pain, stiffness, and dizziness. Identifying these symptoms can help in timely treatment with ubrogepant to inhibit the protein CGRP in the brain responsible for migraines.

The research conducted by Dr. Richard B. Lipton and his team involved 518 participants who were able to predict the onset of migraines within a few hours. Those who took ubrogepant reported being able to function normally two hours after ingestion, with fewer limitations on their activities even after 24 hours.

While promising, ubrogepant may not be effective for those who experience sudden migraine attacks without warning signs. Regardless, experts view this development as a positive step in migraine treatment, providing hope for those who suffer from this common but debilitating condition.

About our experts:

Dr. Steven Ross, a professor and vice chair of clinical affairs in the Department of Neurology at Pennsylvania State University College and Penn State Health, USA, has conducted extensive research in neurology, medicine, and pediatric emergency medicine.

read more:

Source: www.sciencefocus.com

Rare genetic mutations may enhance treatment efficacy for migraine headaches

Posted on by
Reply

Migraines can cause debilitation

Nikki Lloyd/Getty Images

An analysis of the genomes of 1.3 million people has revealed dozens of variations associated with migraine, which could lead to more effective treatments for migraines.

Up to 20% of adults worldwide are thought to experience migraines. Migraines are recurring headaches that are often difficult to treat and can interfere with daily life. Some people have sensory symptoms, such as flashing lights or tingling in the body, before the headache begins, but others do not. It is not known why these two types of migraine, known as migraine with aura and migraine without aura, exist.

“While it is well known that migraines run in families, it has not been easy to identify a clear genetic basis for each subtype,” he says. Debbie Hay at the University of Otago in New Zealand.

now, Kari Stephenson Researchers from the Icelandic biopharmaceutical company deCODE Genetics have identified a genetic variation that appears to influence whether people develop migraines.

Researchers analyzed the DNA of 1.3 million people in Iceland, Denmark, the UK, the US and Norway, and found that around 80,000 of them had experienced migraines.

They discovered 44 genetic mutations associated with the condition, 12 of which had never been reported before. Among these, the research team PRRT2 Genes that help control signaling between neurons are correlated with a greater risk of migraine with aura and epilepsy.

the other A rare mutant that suppresses the function of a gene SCN11A and KCNK5which play a role in transporting sodium and potassium between cells, respectively, and appear to prevent both types of migraines.

The discovery could lead to new treatments that target the causes of migraines, such as drugs that can inhibit the production of a protein encoded by migraines. SCN11A and KCNK5 gene.

“Findings like this should bring great hope to people who suffer from migraine,” Stefansson said. “Current treatments cannot completely eliminate the tendency to develop migraines, so there is a lot of room for better treatments.”

“While great advances have been made in migraine treatment recently, there is still much work to be done in understanding the mechanisms of migraine and how to tailor treatment to each patient,” Hay says.

topic:

Source: www.newscientist.com